Roche's Tiragolumab Fails Phase 3 Trial in Lung Cancer, Plans Further Research
Roche's SKYSCRAPER-01 trial failed to show a survival benefit from adding tiragolumab, a TIGIT-targeting immunotherapy, to Tecentriq in patients with advanced non-small cell lung cancer (NSCLC). Conducted on 534 participants with high PD-L1 expression, the trial did not meet its primary endpoint of extending overall survival, despite earlier interim data suggesting potential benefits[1][2]. While no new safety concerns arose, the results were a setback for Roche, which now plans to reassess its tiragolumab strategy and gather further data from ongoing studies in different cancer types[2].
References
Explore Further
What specific factors contributed to the lack of statistical improvement in survival rates for Roche's tiragolumab in the SKYSCRAPER-01 trial?
How might Roche's strategy for tiragolumab change, considering the broader industry interest in TIGIT inhibitors?
What lessons could other pharmaceutical companies, such as Merck and AstraZeneca, learn from Roche's experience with tiragolumab?
Are there ongoing clinical trials for tiragolumab in other cancer types, and what outcomes are being anticipated?
How has the failure of tiragolumab in the SKYSCRAPER-01 trial impacted investor confidence in Roche and similar TIGIT-targeting therapies?